FDA grants regular approval for Tabrecta use in NSCLC after follow-up data
GlobalData expects Novartis’ Tabrecta to maintain its US market-leading position in non-small cell lung cancer (NSCLC).
By
Oncology
Latest in
Oncology
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
Progression-free survival is the primary endpoint of the Phase II portion of the trial.
Anixa starts subject treatment in Phase I ovarian cancer cell therapy trial
The chimeric endocrine receptor T-cell therapy of the company acts on the follicle stimulating hormone receptor.
Pipeline Moves: Lilly completes Phase II rheumatoid arthritis trial, next phase prospects rise
The Clinical Trials Arena team also investigate treatment candidates in colorectal cancer, retinal vein occlusion, and Raynaud’s disease.
By
ALX starts Phase II trial of colorectal cancer combo therapy
The investigator-sponsored, open-label, single-arm, multicentre trial is being managed by contract research organisation Criterium.
Greenwich begins Phase III trial of immunotherapy for breast cancer
The trial will assess the safety and efficacy of GLSI-100 in patients with HER2/neu positive breast cancer.
Gamida doses first subject in Phase I/II cell therapy trial for lymphomas
The Phase II expansion portion of the trial will assess GDA-201’s safety and efficacy in two cohorts of 63 subjects.
Peel Therapeutics begins Phase I solid tumour trial
The trial will assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.